Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: BPRDP-056; T-1201

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Targeting Technologies; National Health Research Institutes
  • Developer Taivex Therapeutics
  • Class Amines; Antineoplastics; Camptothecins; Drug conjugates; Indolizines; Pyrans; Quinolines; Small molecules; Zinc compounds
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Feb 2024 National Health Research Institutes and Molecular Targeting Technologies files for patent protection with WIPO for BPRDP 056 in multiple countries worldwide prior to February 2024 (Taivex Therapeutics pipeline, February 2024).
  • 27 Feb 2024 National Health Research Institutes and Molecular Targeting Technologies has patent protection for BPRDP 056 in USA, Taiwan, Japan, Australia, South Korea, New Zealand, India, European Union and other undisclosed countries prior to February 2024 (Taivex Therapeutics pipeline, February 2024).
  • 24 Jun 2021 Phase-I clinical trials in Solid tumours (Late-stage disease) in Taiwan (IV) (NCT04866641)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top